Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $6.35 Analyst target: $4.49 Upside: -29.34%
Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah.
See the full interactive analysis & chart →Informational only — not investment advice.